Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation
- 52 Downloads
Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is a powerful device for treatment of patients with life-threatening heart failure. Although bleeding is often associated with VA ECMO and sometimes results in a fatal outcome, its precise causes remain unknown. On the other hand, excessive high shear stress in the cardiovascular system causes acquired von Willebrand syndrome (aVWS), characterized by loss of von Willebrand factor (vWF) large multimers. vWF large multimers of five consecutive patients treated with VA ECMO were quantitatively evaluated using the vWF large multimer indices, defined as the ratio of the large multimer ratio of a patient to that of a healthy subject analyzed simultaneously. All 5 patients exhibited oozing type of bleeding at the skin insertion sites under treatment with PCPS at flow rates of 2.5–3.0 l/min/m2, including two severe cases of bleeding; one patient had massive gastrointestinal bleeding and another had hemothorax. Their vWF large multimer indices were 20.8, 28.8, 27.6, 51.0, and 31.0% (means 31.8 ± 11.4%). Surprisingly, these values are much lower than those observed in severe aortic stenosis reported previously by us (Tamura et al. in J Atheroscler Thromb 22:1115–1123, 2015), where vWF multimer indices in 31 severe aortic stenosis patients with peak pressure gradient through the aortic valves of 85.1 ± 29.4 mmHg were 75.0 ± 21.7% (p < 0.0001), indicating that much higher grade of aVWS occurred in patients with VA ECMO than severe aortic stenosis patients. All the 5 patients treated with VA ECMO developed aVWS that was much more severe than in patients with severe aortic stenosis.
KeywordsVA ECMO Bleeding Acquired von Willebrand syndrome Aortic stenosis Large VWF multimer index
This study was partly supported by a Health and Labour Sciences Research Grant for the ‘Research on rare and intractable diseases’ from the Ministry of Health, Labour and Welfare, Japan, to HH and YN, and grants from the SENSHIN Medical Research Foundation and the Suzuken Memorial Foundation to HH.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Tamura T, Horiuchi H, Imai M, Tada T, Shiomi H, Kuroda M, Nishimura S, Takahashi Y, Yoshikawa Y, Tsujimura A, Amano M, Hayama Y, Imamura S, Onishi N, Tamaki Y, Enomoto S, Miyake M, Kondo H, Kaitani K, Izumi C, Kimura T, Nakagawa Y. Unexpectedly high prevalence of acquired von Willebrand syndrome in patients with severe aortic stenosis as evaluated with a novel large multimer index. J Atheroscler Thromb. 2015;22:1115–23.CrossRefGoogle Scholar
- 4.Haberichter SL, Montgomery RR. Structure and function of von Willebrand factor. In: Marder VJ, Aird WC, Bennett JS, Schulman S, GWhite GC, editors. Hemostasis and thrombosis. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 197–207.Google Scholar
- 6.Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, Working Party on von Willebrand Disease, C. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103–14.CrossRefGoogle Scholar
- 13.Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57:1140–3.Google Scholar